基于OCT的视网膜参数和胆道血管指数预测在炎症性肠病中对抗TNF-α治疗的反应
Fenying Lu1, Yuechen Du1, Yijie Gu1
1Department of Gastroenterology, Affiliated Changshu Hospital of Nantong University, Jiangsu, China.
Photodiagnosis and photodynamic therapy
|October 18, 2025
概括
光学连贯断层扫描 (OCT) 可以预测炎症性肠病 (IBD) 患者的视网膜病变进展. OCT参数还可以预测对TNF-α抑制剂治疗的反应,帮助治疗决策.
科学领域:
- 眼科医生 眼科 眼科
- 胃肠病学 胃肠病学
- 生物标志物发现发现
背景情况:
- 炎症性肠病 (IBD) 患者有视网膜病变的风险.
- 眼部生物标志物可以预测疾病进展和治疗反应.
研究的目的:
- 评估光学连贯性断层扫描 (OCT) 参数,以预测IBD患者视网膜病变的进展.
- 评估OCT在预测对TNF-α抑制剂治疗的反应中的有效性.
主要方法:
- 对180名IBD患者 (克罗恩病和性结肠炎) 的回顾性分析.
- 视网膜神经纤维层 (RNFL),状细胞内状层 (GCIPL),中央黄斑厚度 (CMT) 和胆道血管密度指数 (CVI),胆道毛细血管血管密度 (CC-VD),底胆道血管厚度 (SF-CT) 的OCT测量.
- 接收器操作特征 (ROC) 曲线分析和名ogram构造用于预测建模.
主要成果:
- 预测IBD结局的高AUC值:RNFL (0.907),GCIPL (0.939),CMT (0.871),CVI (0.918),CC-VD (0.965),SF-CT (0.946) 的结果.
- 在GCIPL,CVI和CC-VD中,生物治疗反应的预测值很高 (AUC:0.952,0.941,0.993).
结论:
- 来自OCT的视网膜和胸膜参数有效预测IBD疾病的结果.
- 这些生物标志物为评估IBD对生物疗法的反应提供了有价值的指导.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
635
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
635
Inflammatory Bowel Disease II: Crohn's Disease
947
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
947
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
429
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
429
Inflammatory Bowel Disease IV: Pharmacological Management
496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
496


